Boehringer Ingelheim begins phase IIa trial of BI 765423, a novel monoclonal antibody targeting IL-11, in patients with idiopathic pulmonary fibrosis: Ingelheim, Germany Thursday, ...
Not intended for US and UK audiences BI 765423 has been developed to target IL-11, a key driver of fibrosis New study will investigate potential of BI 765423 to improve lung function for patients with ...
Boehringer Ingelheim advances IL-11 ... • BI 765423 has been developed to target IL-11, a key driver of fibrosis • The potential first-in-class inhibitor is an acquired asset from Enleofen with ...
Not intended for US and UK audiences BI 765423 has been developed to target IL-11, a key driver of fibrosis New study will investigate potential of BI 765423 to improve lung function for patients ...
SHANGHAI, Dec. 30, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Phase II clinical trial of its ...
Clinical Trials Arena on MSN
Mabwell doses first patient in phase II anti-IL-11 antibody trial
The first patient received dosing at Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine.
Booster Therapeutics (Germany) focuses on developing small-molecule proteasome activators for neurodegenerative disease using ...
New research is shedding light on surprising ways to reduce chronic inflammation—including suggestions as simple as flossing ...
A new study published in the Journal of the European Academy of Dermatology & Venerology showed that in children with severe ...
Anti-inflammatory treatment reduced depressive symptoms and anhedonia in patients with elevated inflammation. Learn more.
A recent study published in the journal Breast Cancer Research has found that adolescent girls who engage in regular organised physical activity show favourable changes in breast tissue composition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback